In AML, preclinical studies have shown that IL-15-secreting CAR T or NK cells targeting CLEC12A or CD123 display enhanced cytotoxicity, resistance to exhaustion, and improved survival in xenograft models. Here, CLEC12A is linked to acute myeloid leukemia.